Thymidine phosphorylase levels and dihydropyrimidine dehydrogenase levels in non-small cell lung cancer tissues

被引:1
作者
Chujo, Masao [1 ]
Miura, Takashi [1 ]
Kawano, Yozo [1 ]
Miyawaki, Michiyo [1 ]
Imakiire, Takayuki [1 ]
Hayashita, Yoji [1 ]
Kawahara, Katsunobu [1 ]
机构
[1] Oita Univ, Fac Med, Dept Oncol Sci, Oita 8795593, Japan
关键词
thymidine phosphorylase; dihydropyrimidine dehydrogenase; non-small cell lung cancer; THYMIDYLATE SYNTHASE; TUMOR-TISSUES; EXPRESSION; EFFICACY; CHEMOTHERAPY; CARCINOMA; TEGAFUR; URACIL;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) are the major catabolic enzymes of 5-FU. In this study, we analyzed the concentration of TP and DPD in non-small cell lung cancer tissue by enzyme-linked immunosorbent assay. We measured the TP and DPD levels in 25 adenocarcinoma tissues and 25 squamous cell carcinoma tissues. The mean TP concentration in non-small cell lung cancer tissue was statistically higher than that of normal lung tissue as was the mean DPD concentration. The ratio of the TP level to DPD level in tumor tissue was higher in squamous cell carcinoma than in adenocarcinoma. No significant difference could be detected between the TP level, DPD level, or TP/DPD level and the tumor size or lymph node metastasis. In conclusion, chemotherapy with 5-FU may be more effective in squamous cell lung cancer patients than lung adenocarcinoma patients from the result of the ratio of TP to DPD.
引用
收藏
页码:777 / 780
页数:4
相关论文
共 18 条
  • [1] Increased dihydropyrimidine dehydrogenase activity in breast cancer
    Anan, K
    Mitsuyama, S
    Tamae, K
    Suehara, N
    Nishihara, K
    Ogawa, Y
    Abe, YJ
    Iwashita, T
    Toyoshima, S
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 2003, 82 (03) : 174 - 179
  • [2] Relationships between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase and cell proliferative activity and 5-fluorouracil sensitivity in colorectal carcinoma
    R. Fujii
    A. Seshimo
    S. Kameoka
    [J]. International Journal of Clinical Oncology, 2003, 8 (2) : 72 - 78
  • [3] FUKUKAWA T, 1992, NATURE, V356, P668
  • [4] Huang CL, 2000, INT J ONCOL, V17, P47
  • [5] Igarashi M, 1998, CANCER, V82, P1225, DOI 10.1002/(SICI)1097-0142(19980401)82:7<1225::AID-CNCR3>3.0.CO
  • [6] 2-E
  • [7] Ishikawa T, 1998, CANCER RES, V58, P685
  • [8] A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung
    Kato, H
    Ichinose, Y
    Ohta, M
    Hata, E
    Tsubota, N
    Tada, H
    Watanabe, Y
    Wada, H
    Tsuboi, M
    Hamajima, N
    Ohta, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (17) : 1713 - 1721
  • [9] Katsumata K, 2001, ONCOL REP, V8, P127
  • [10] Mori K, 2000, INT J ONCOL, V17, P33